Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:JUNO

Juno Therapeutics (JUNO) Stock Price, News & Analysis

Juno Therapeutics logo

About Juno Therapeutics Stock (NASDAQ:JUNO)

Key Stats

Today's Range
$86.96
$86.96
50-Day Range
$86.96
$86.96
52-Week Range
$19.62
$87.01
Volume
2 shs
Average Volume
5.48 million shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Juno Therapeutics, Inc. (Juno) is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. The Company is developing cell-based cancer immunotherapies based on its chimeric antigen receptor (CAR) and T cell receptor (TCR) technologies to genetically engineer T cells to recognize and kill cancer cells. Its product candidates JCAR017, JCAR014, and JCAR015, as well as an additional early stage product candidate incorporating a fully human binding domain, leverage CAR technology to target CD19, a protein expressed on the surface of almost all B cell leukemias and lymphomas. Its CAR product candidate JCAR018 targets CD22, a different protein commonly expressed on the surface of B cell leukemias and lymphomas. Its MUC-16 directed product candidate is an armored CAR that secretes the cytokine interleukin 12 (IL-12), which may help to overcome the inhibitory effects that the tumor microenvironment can have on T cell activity.

Receive JUNO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Juno Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

JUNO Stock News Headlines

Shape Therapeutics CEO departs, interim named
Blackrock’s Sending THIS Crypto Higher on Purpose
It's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…
See More Headlines

JUNO Stock Analysis - Frequently Asked Questions

Juno Therapeutics Inc (NASDAQ:JUNO) posted its earnings results on Wednesday, November, 1st. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.80) by $0.07. The firm's revenue was up 115.4% on a year-over-year basis.

Juno Therapeutics (JUNO) raised $153 million in an initial public offering (IPO) on Friday, December 19th 2014. The company issued 9,300,000 shares at a price of $15.00-$18.00 per share. Morgan Stanley, J.P. Morgan and Goldman Sachs served as the underwriters for the IPO and Leerink Partners was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Juno Therapeutics investors own include Bristol-Myers Squibb (BMY), (KITE) (KITE), bluebird bio (BLUE), Gilead Sciences (GILD), Meta Platforms (META), Puma Biotechnology (PBYI) and BioMarin Pharmaceutical (BMRN).

Company Calendar

Last Earnings
11/01/2017
Today
11/22/2024

Industry, Sector and Symbol

Sector
N/A
Industry
N/A
Sub-Industry
N/A
Current Symbol
NASDAQ:JUNO
Fax
N/A
Employees
N/A
Year Founded
N/A

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Optionable
Beta
N/A
(Almost)  Everything You Need To Know About The EV Market Cover

Click the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise.

Get This Free Report

This page (NASDAQ:JUNO) was last updated on 11/22/2024 by MarketBeat.com Staff
From Our Partners